期刊文献+

环磷酰胺联合氟达拉滨方案以及沙利度胺治疗华氏巨球蛋白血症15例疗效分析 被引量:5

Clinical observation of FC plus thalidomide treatment of macroglobulinemia
原文传递
导出
摘要 Waldenstorm巨球蛋白血症(WM)是一种原因未明的B淋巴浆细胞恶性增生性疾病,以合成及分泌单克隆IgM型球蛋白的淋巴样浆细胞恶性增生为特征,该病多见于老年人,发病率较低。目前治疗主要为烷化剂、核苷类似物、利妥昔单抗、硼替佐米及造血干细胞移植等。我院自2009年1月至2013年6月应用环磷酰胺以及氟达拉滨(FC)方案联合沙利度胺治疗WM患者15例,取得一定疗效,现报道如下。
出处 《中国实用内科杂志》 CAS CSCD 北大核心 2014年第3期297-298,共2页 Chinese Journal of Practical Internal Medicine
关键词 华氏巨球蛋白血症 氟达拉滨 环磷酰胺 沙利度胺 macroglobulinemia fludarabine cyclophosphamide thalidomide
  • 相关文献

参考文献2

二级参考文献44

  • 1ANSELL S M,KYLE R A,REEDER C B,et al. Diag- nosis and management of Waldenstrom macroglobu- linemia:Mayo stratification of macroglobulinemia and risk-adapted therapy(mSMART)guidelines[J]. Mayo Clin Proc, 2010,85 : 824- 833.
  • 2WON Y W,KIM S J,KIM K,et al. Clinical features and treatment outcomes of lymphoplasmacytic lym- phoma..a single center experience in Korea[J]. AnnHematol,2010,89 : 1011- 1018.
  • 3DIMOPOULOS M A,GERTZ M A, KASTRIFIS E, et al. Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's MaeroglohuLinemia[J]. J Clin Oneol, 2009,27 : 120 - 126.
  • 4LIN P,BUESO-RAMOS C,WlLSON C S,et al. Wal- denstrom macroglobulinemia involving extramedullary sites: morphologic and immunophenotypic findings in 44 patients[J].Am J Surg Pathol, 2003,27 : 1104 - 1113.
  • 5ROURKE M, ANDERSON K C, GHOBRIAL I M. Review of clinical trials conducted in Waldenstrom macroglobulinemia and recommendations for repor- ting clinical trial responses in these patients[J].Leuk Lymphoma, 2010,25 : 1779- 1792.
  • 6WALDENSTROM J. To treat or not to treat,this is the real question[J].Leuk Res,1991,15 :407-408.
  • 7DIMOPOULOS M A, HAMILOS G, EFSTATHIOU E,et al. Treatment of Waldenstrom's macroglobuline- mia with the combination of fludarabine and cyclo- phosphamide[J].Leuk Lymphoma, 2003,44:993 - 996.
  • 8TAM C S,WOLF M M,WESTERMAN D,et al. Flu- darabine combination therapy is highly e{fective in first-line and salvage treatment of patients with Wal- denstrom" s macroglobulinemia [J ]. Clin Lymphoma Myeloma, 2005,6 : 136- 139.
  • 9LELEU X,TMABURINI J,ROCCARO A, et al. Bal- ancing risk versus benefit in the treatment of Walden- strom's Macroglobulinemia patients with nucleoside analogue-based therapy[J].Clin Lymphoma Myelo- ma,2009,9:71-73.
  • 10TAMBURINI J, LEVY V, CHALETEIX C, et al. Fludarabine plus eyclophosphamide in Waldenstrom's maeroglobulinemia:results in 49 patients[J].Leuke- mia, 2005,19 : 1831- 1834.

共引文献5

同被引文献76

  • 1蒋道怡,王红,郭建军.主要表现为贫血的原发性巨球蛋白血症[J].临床误诊误治,2005,18(9):636-636. 被引量:2
  • 2余胜珠,杨光华,冯金梅.参芪扶正注射液联合化疗治疗恶性肿瘤86例临床观察[J].中西医结合学报,2006,4(1):84-86. 被引量:8
  • 3王宁,黄林平.参芪扶正注射液对淋巴细胞的作用[J].中国中西医结合外科杂志,2006,12(2):139-142. 被引量:21
  • 4汤献猷.现代肿瘤学[M].上海:复旦大学出版社,2003:820.
  • 5Owen R G, Treon S P, A1 Katib A, et al. Clinicopatho- logical definition of Waldenstrom "s macroglobulinemia: consensus panel recommendations from the Second Inter- national Workshop on Waldenstrom "s Macroglobulinemia [J]. Semin Oncol, 2003,30(2) :110-115.
  • 6Treon S P, Hunter Z R, Aggarwal A, et al. Characteriza- tion of familial Waldenstroms macroglobulinemia[ J]. Ann Oncol, 2006,17 ( 3 ) :488-494.
  • 7Ansell S M, Kyle R A, Reeder C B, et al. Diagnosis and management of Waldenstrom macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted thera- py (mSMART) guidelines[ J]. Mayo Clin Proc, 2010,85 (9) :824-833.
  • 8Gertz M A, Merhni G, Treon S P. Amyloidosis and Wal- denstrom "s macroglobulinemia [ J ]. Hematology ( Am Soc Hematol Educ Program) , 2004:257-282.
  • 9Gertz M A. Waldenstrom macroglobulinemia [ J]. Hema- tology, 2012,17 ( Suppl 1 ) : 112-116.
  • 10Sekhar J, Sanfilippo K, Zhang Q, et al. Waldenstrom macroglobulinemia: a Surveillance, Epidemiology, and End Results database review from 1988 to 2005 [ J]. Leuk Lymphoma, 2012,53 ( 8 ) : 1625-1626.

引证文献5

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部